Peptides / Growth hormone axis

Synthetic fragment · 29 amino acids · 3,357.9 Da

Sermorelin

WithdrawnBanned in sport

Sermorelin is a synthetic form of the first 29 amino acids of growth hormone-releasing hormone. It was approved in the US and withdrawn in 2009 for reasons other than safety, and studies in people measured growth hormone and growth in children. PepBank shows 248 results on sermorelin from 43 studies in people, and 56 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as GHRH(1-29)NH2, GRF(1-29)NH2, GEREF, Geref Diagnostic, Groliberin, Sermorelin acetate

29 amino acids, from first to last1 changed amino acid

Evidence level: Some studies in people248 of 304 results come from studies in people.

Results in people

248

82% of 304 results

Results in animals

12% of 304 results

Results in lab cells

7% of 304 results

From computer models

0% of 304 results

Overview

Sermorelin at a glance

What it is	Synthetic fragment, 29 amino acids
Approval	US approval withdrawn in 2009 because the maker stopped selling it. The FDA found the withdrawal was not for safety or effectiveness reasons (Geref, first approved 1990)
In sport	Banned in sport (WADA S2.2.4)
Studies	101 studies with results. 60 of them gave sermorelin, with 304 results. 248 in people36 in animals20 in lab cells
Best study in people	Randomized controlled trial with 60 people (1993)
Clinical trials	None registered
Community use	Raising growth hormone for adult anti-aging and wellness; Sleep quality and recovery; Body composition

The science

What is sermorelin?

Synthetic 1-29 fragment of human growth hormone-releasing hormone. Approved in the United States in 1990 and 1997; both products were discontinued.

Amino acids in one chain

The history of sermorelin

1984
The oldest paper on sermorelin in PepBank is from 1984.
1990December
FDA approved Geref for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone.
1997September
FDA approved Geref for treatment of idiopathic growth hormone deficiency in children with growth failure.

Sermorelin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 29 amino acidsFrom the first amino acid to the last

Y1A−DAI5FTNSY10+R+KVLG15QLSA+R20+KLLQ−D25IMS+R

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Sermorelin is a synthetic fragment of 29 amino acids, with no ring, 1 changed amino acid.

Formula

C₁₄₉H₂₄₆N₄₄O₄₂S

Molecular weight

3,357.9 g/mol

CAS number

86168-78-7

Target

Growth hormone-releasing hormone receptor (gene GHRHR): agonistEvidence: ChEMBL mechanism

Development

EMD Serono (Merck Serono); products discontinued. Highest phase: past the trial stage (see status).

Identifiers

PubChem 16132413, ChEMBL CHEMBL1201490, UNII 89243S03TE, DrugBank DB00010, KEGG D08509, IUPHAR 6998

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

InChIKey
WGWPRVFKDLAUQJ-MITYVQBRSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What sermorelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people248 of 304 results come from studies in people.

Growth hormone and growth

192 results · 162 in people · 28 animal · 2 lab

In healthy older men and women, the GHRH analog raised overnight growth hormone release. The Journal of clinical endocrinology and metabolism, 1997

Top results

In healthy older men and women, the GHRH analog raised overnight growth hormone release. (The Journal of clinical endocrinology and metabolism, 1997)
In children with growth hormone deficiency, 30 micrograms/kg/day GHRH(1-29)-NH2 gave less growth than growth hormone. (Acta paediatrica, 1993)
In older men and women, a nightly GHRH analog dose triggered a quick release of growth hormone within 10 minutes. (The Journal of clinical endocrinology and metabolism, 1997)

Immune system and inflammation

31 results · 24 in people · 7 lab

In children with growth hormone deficiency, all 20 children on high-dose GHRH(1-29)-NH2 developed antibodies against GHRH. Acta paediatrica, 1993

Top results

In children with growth hormone deficiency, all 20 children on high-dose GHRH(1-29)-NH2 developed antibodies against GHRH. (Acta paediatrica, 1993)
In healthy older men and women, the GHRH analog raised the number of activated immune cells carrying CD71. (The Journal of clinical endocrinology and metabolism, 1997)
In children with growth hormone deficiency, 14 developed antibodies against GHRH during treatment. (Lancet, 1987)

Blood sugar

7 results · 7 in people

In older men and women, the GHRH analog did not change fasting insulin levels. The Journal of clinical endocrinology and metabolism, 1997

Top results

In older men and women, the GHRH analog did not change fasting insulin levels. (The Journal of clinical endocrinology and metabolism, 1997)
In children with growth hormone deficiency, daily GHRH did not change fasting blood sugar. (The Journal of clinical endocrinology and metabolism, 1996)
Fasting blood glucose rose during treatment. (Clinical endocrinology, 1994)

Hormones

5 results · 5 in people

In five healthy men, the GHRH peptide did not change blood levels of other hormones or glucose. Peptides, 1985

Top results

In five healthy men, the GHRH peptide did not change blood levels of other hormones or glucose. (Peptides, 1985)
The GHRH peptide caused a small short rise in prolactin, but the total prolactin response did not change. (Clinical endocrinology, 1986)
Adding the GHRH peptide to two other releasing hormones gave a bigger thyroid-stimulating hormone rise than the two hormones alone. (Clinical endocrinology, 1986)

Weight and appetite

6 results · 4 in people · 2 animal

In older men and women, the GHRH analog caused no other changes in body composition. The Journal of clinical endocrinology and metabolism, 1997

Top results

In older men and women, the GHRH analog caused no other changes in body composition. (The Journal of clinical endocrinology and metabolism, 1997)
In older men and women, the GHRH analog did not change body weight. (The Journal of clinical endocrinology and metabolism, 1997)
In older men and women, the GHRH analog showed a trend toward positive nitrogen balance, significant only when men and women were combined. (The Journal of clinical endocrinology and metabolism, 1997)

Bones and joints

2 results · 2 in people

In children with growth hormone deficiency after radiation, bone age advanced by about 1.1 years for each year of GHRH treatment. Clinical endocrinology, 1997

Top results

In children with growth hormone deficiency after radiation, bone age advanced by about 1.1 years for each year of GHRH treatment. (Clinical endocrinology, 1997)
In older men and women, the GHRH analog did not change bone mineral density. (The Journal of clinical endocrinology and metabolism, 1997)

All 101 sermorelin studies by area Open the Scientific page

Key sermorelin studies

Studies in people come first, then studies in animals and in the lab.

People
A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency
Chen et al. 1993 · Acta paediatrica (Oslo, Norway : 1992). Supplement · 60 people · cited by 4
12 results
People
Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone
Neyzi et al. 1993 · Acta paediatrica (Oslo, Norway : 1992). Supplement · 43 people · cited by 6
8 results
People
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women
Khorram et al. 1997 · The Journal of clinical endocrinology and metabolism · 19 people · cited by 25
21 results
People
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women
Khorram et al. 1997 · The Journal of clinical endocrinology and metabolism · 19 people · cited by 25
26 results
People
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals
Achermann et al. 1999 · Clinical endocrinology · 12 people · cited by 2
5 results

All 101 Sermorelin studies

Sermorelin clinical trials

ClinicalTrials.gov lists no trial of sermorelin. A trial under another name may exist.

Status and safety

Is sermorelin approved?

FDA

United States

Withdrawn

Withdrawn.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.4.

No longer. US approval withdrawn in 2009 because the maker stopped selling it. The FDA found the withdrawal was not for safety or effectiveness reasons (Geref, first approved 1990). The maker told the FDA it stopped selling the product. The FDA later found that the products were not withdrawn from sale for reasons of safety or effectiveness. Banned in sport (WADA S2.2.4).

Laws and labels change, so check the regulator for the current status.

Sermorelin side effects and safety

PepBank has 30 safety results from studies of sermorelin. 30 of them come from studies in people.

Safety results from studies (30)

In children with growth hormone deficiency, all 20 children on high-dose GHRH(1-29)-NH2 developed antibodies against GHRH. (Acta paediatrica, 1993)
In healthy older men and women, no side effects were reported with the GHRH analog. (The Journal of clinical endocrinology and metabolism, 1997)
In older men and women, the only side effect of the GHRH analog was a short rise in blood fats that went away. (The Journal of clinical endocrinology and metabolism, 1997)
In children with growth hormone deficiency, daily GHRH caused no harmful changes in routine blood or hormone tests. (The Journal of clinical endocrinology and metabolism, 1996)
In children with growth hormone deficiency, 14 developed antibodies against GHRH during treatment. (Lancet, 1987)
Fasting blood glucose rose during treatment. (Clinical endocrinology, 1994)
In children treated with GHRH(1-29)-NH2, blood chemistry and hormone tests showed no harmful changes. (Clinical endocrinology, 1997)
In children with chronic kidney failure, blood urea and creatinine stayed stable during GHRH treatment. (Medicina, 1996)
In children given nasal GHRH, three of eight made antibodies against GHRH within 6 weeks. (Acta paediatrica, 1993)
In five healthy men, the only side effect was short flushing at the highest dose. (Peptides, 1985)
In five children, the only side effect was burning of the nose lining in one child. (Acta endocrinologica. Supplementum, 1986)
In normal men, the analog raised growth hormone by all three routes with no reported adverse effect. (Clinical pharmacology and therapeutics, 1986)
In children with growth hormone deficiency, 19 of 20 children on low-dose GHRH(1-29)-NH2 developed antibodies against GHRH. (Acta paediatrica, 1993)
In children with growth hormone deficiency on GHRH(1-29)-NH2, no antibodies against growth hormone were found. (Acta paediatrica, 1993)
In children with growth hormone deficiency, antibodies against GHRH had almost gone 9 months after stopping GHRH(1-29)-NH2. (Acta paediatrica, 1993)
In children with growth hormone deficiency on GHRH(1-29)-NH2, no serious side-effects were seen. (Acta paediatrica, 1993)
In children with growth hormone deficiency, three children on GHRH(1-29)-NH2 reported mild irritation where they were injected. (Acta paediatrica, 1993)
In children with growth hormone deficiency, daily GHRH did not change fasting blood sugar. (The Journal of clinical endocrinology and metabolism, 1996)
In children with growth hormone deficiency, daily GHRH did not cause excessive IGF-I levels. (The Journal of clinical endocrinology and metabolism, 1996)
In children with growth hormone deficiency, daily GHRH was well tolerated overall. (The Journal of clinical endocrinology and metabolism, 1996)
Fasting insulin levels rose during treatment. (Clinical endocrinology, 1994)
In 4 of 14 children who had earlier taken growth hormone, growth slowed on GHRH injections, for unknown reasons. (Lancet, 1987)
In children with growth hormone deficiency, the antibodies against GHRH did not seem to harm growth or the growth hormone response. (Lancet, 1987)
In children treated with GHRH(1-29)-NH2, no side effects were linked to the treatment. (Clinical endocrinology, 1997)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
30 micrograms/kg/day	Human	human	Not reported	6 months	Randomized trial in people · n = 60	Chen 1993
60 micrograms/kg/day	Human	human	Not reported	6 months	Randomized trial in people · n = 60	Chen 1993
30 and 60 micrograms/kg/day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 43	Neyzi 1993
30 micrograms/kg/day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 43	Neyzi 1993
30 and 60 micrograms/kg/day	Human	human	Not reported	6 months	Randomized trial in people · n = 40	Chen 1993
10 micrograms/kg	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 19	Khorram 1997
10 microg/kg	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 19	Khorram 1997
60 ng/kg/minutes	Human	human	subcutaneous	24 h	Randomized trial in people · n = 12	Achermann 1999
10 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 10	Spoudeas 1994
100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 10	Spoudeas 1994
1 microgram	Human	human	intravenous	Not reported	Randomized trial in people · n = 10	Spoudeas 1994
10 and 100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 10	Spoudeas 1994
1, 10 and 100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 10	Spoudeas 1994
100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 9	Giustina 1993
0.05, 0.15 and 1.0 μg/kg	Human	human	intravenous bolus	single bolus	Randomized trial in people · n = 5	Achermann 2000
60 micrograms/kg/day	Human	human	subcutaneous	6 months	Randomized trial in people	Neyzi 1993
0.25 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people	Wilton 1993
1-2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people	Wilton 1993
about 50 micrograms/kg	Human	human	intranasal	Not reported	Randomized trial in people	Wilton 1993
30 micrograms/kg/day	Human	human	subcutaneous	up to 1 yr	Trial in people without random groups · n = 110	Thorner 1996
1 microgram/kg BW	Human	human	intravenous	single dose	Trial in people without random groups · n = 86	Ranke 1986
1 microgram/kg	Human	human	intravenous	single injection	Trial in people without random groups · n = 36	Gelander 1989
1 microgram/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 22	Ramirez 1995
20 micrograms/kg twice daily	Human	human	subcutaneous	12 months	Trial in people without random groups · n = 18	Kirk 1994
200 micrograms	Human	human	intravenous bolus	single dose	Trial in people without random groups · n = 17	Grossman 1985
5 micrograms/kg	Human	human	subcutaneous	6 months	Trial in people without random groups · n = 11	Hernández 1988
1 microg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 11	Bellone 2000
25 ng/kg.min	Human	human	intravenous	90 min	Trial in people without random groups · n = 10	Soule 1994
3-4 micrograms/kg b.d. or once daily, then 8-10 micrograms/kg once daily	Human	human	subcutaneous	11 months including treatment-free intervals	Trial in people without random groups · n = 9	Hümmelink 1987
3-4 micrograms/kg once daily	Human	human	subcutaneous	3 months	Trial in people without random groups · n = 9	Hümmelink 1987
3-4 micrograms/kg twice daily	Human	human	subcutaneous	3 months	Trial in people without random groups · n = 9	Hümmelink 1987
8-10 micrograms/kg once daily	Human	human	subcutaneous	3 months	Trial in people without random groups · n = 9	Hümmelink 1987
15 micrograms/kg twice daily	Human	human	subcutaneous	1 year	Trial in people without random groups · n = 9	Ogilvy-Stuart 1997
26 +/- 2.4 micrograms/kg/day	Human	human	subcutaneous	3 to 6 months	Trial in people without random groups · n = 9	Pasqualini 1996
60 ng/kg/min	Human	human	subcutaneous infusion	up to 1 year	Trial in people without random groups · n = 8	Brain 1990
50 micrograms/kg three times per day	Human	human	intranasal	6 months	Trial in people without random groups · n = 8	Hümmelink 1993
100 micrograms	Human	human	intravenous	single bolus	Trial in people without random groups · n = 7	Giustina 1989
0.015 to 0.5 micrograms/kg body weight	Human	human	intravenous bolus	Not reported	Trial in people without random groups · n = 5	Barron 1985
100 micrograms/kg body weight	Human	human	intranasal	Not reported	Trial in people without random groups · n = 5	Borkenstein 1986
0.1 and 1.0 micrograms/kg	Human	human	intravenous	two pulses weekly over 4 weeks	Trial in people without random groups · n = 4	Dattani 1996

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Community sources describe sermorelin as a growth hormone-releasing hormone fragment that people inject under the skin at bedtime on an empty stomach. The common amount is 200-300 mcg. Many also pair it with ipamorelin.

Reported routines and cautions

What people use it for

Raising growth hormone for adult anti-aging and wellnessS1S2
Sleep quality and recoveryS1S2
Body compositionS1S2

Reported regimens

Regimens that community sources report for Sermorelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Nightly dosing for adult wellness or anti-aging	subcutaneous injectionabout 30 to 60 minutes before sleep, on an empty stomach	200 to 300 mcg per dose	once daily at bedtime; S2 says 5 to 7 nights a week	3 to 6 months, then a lower-frequency schedule	2 sources agree on 200-300 mcg at bedtime. Both are wikis that compile other pages. Both sources carry seller links.	S1S2
Higher doses prescribed by anti-aging clinics	subcutaneous injection	300 to 1000 mcg per dose	once daily at bedtime	6 to 12 months (S1)	sources differ: 500-1000 mcg (S1) against 300-500 mcg (S2). The range here is not an average. Both sources carry seller links.	S1S2
Stack with ipamorelin	subcutaneous injectionthe two are given together	200 to 300 mcg per dose of each peptide	once daily at bedtime	3 to 6 months	2 sources agree on 200-300 mcg of each peptide at bedtime. Both are wikis that compile other pages. Both sources carry seller links.	S1S2
Maintenance after the first months	subcutaneous injection	500 to 1000 mcg per dose	2 to 3 times per week	ongoing	single source. The source carries seller links.	S1

Reported side effects

injection-site redness, itching, pain or swellingS1S2
facial flushing or warmth after injectionS1S2
headache, mostly in the first 1 to 2 weeksS1S2
mild water retentionS1S2
dizziness or lightheadedness, mostly with first dosesS2
nausea or hives (less common)S2

Reported benefits (claims, not shown in trials)

deeper sleep and more vivid dreams in the first 1 to 2 weeksS1S2
better recovery from exercise at 3 to 4 weeksS1

Cautions

S2 lists active malignancy as a contraindication, because growth hormone and IGF-1 may promote growth of existing tumors.S2
S2 reports that severe allergic reactions are rare and need immediate medical attention.S2
S1 reports that product quality varies a lot between compounding pharmacies and peptide vendors.S1
S1 reports these are self-reports without controls, blinding or objective measures.S1
S1 reports that community doses (200-300 mcg) are lower than doses used in clinical studies, and that no large trial tested sermorelin with ipamorelin.S1

Status notes

Sermorelin was approved as Geref for children with growth failure and as a diagnostic agent. The maker stopped selling it in 2008. The FDA stated in 2013 that Geref was not withdrawn from sale for reasons of safety or effectiveness.S2S3
Use for adult anti-aging is not an approved use. S2 reports that it is prescribed through compounding pharmacies.S2

Community sources

S1Sermorelin: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2Sermorelin: GHRH Analog for Natural Growth Hormonepeptidepedia.orgcarries seller links, not linked
S3Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness (opens in a new tab)federalregister.gov

Gaps

No forum threads could be read (Reddit is blocked; ExcelMale returned HTTP 403). Only two community sources, and both are wikis that compile other pages. S2 carries a vendor advertisement in its footer. No current approved product label exists in the US, so no label regimen is given. Current FDA compounding status of sermorelin was not confirmed from a primary FDA page; some secondary sources conflict.

Questions and more

Ask a question about sermorelin

The answer links to every study it uses.

What does the evidence say about sermorelin?Is sermorelin tested in people?Compare with Hexarelin Compare with GHRP-6

Sources

Database: PepBank data for sermorelin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about sermorelin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Sermorelin

WithdrawnBanned in sport

Also known as GHRH(1-29)NH2, GRF(1-29)NH2, GEREF, Geref Diagnostic, Groliberin, Sermorelin acetate

What it is

Synthetic fragment, 29 amino acids

Approval

US approval withdrawn in 2009 because the maker stopped selling it. The FDA found the withdrawal was not for safety or effectiveness reasons (Geref, first approved 1990)

In sport

Banned in sport (WADA S2.2.4)

Studies

101 studies with results. 60 of them gave sermorelin, with 304 results.
248 in people36 in animals20 in lab cells

Best study in people

Randomized controlled trial with 60 people (1993)

Clinical trials

None registered

Community use

Raising growth hormone for adult anti-aging and wellness; Sleep quality and recovery; Body composition

Dose as reported

Class

Species

Route

Duration

Design

Source

30 micrograms/kg/day

Human

human

Not reported

6 months

Randomized trial in people · n = 60

Chen 1993

60 micrograms/kg/day

Human

human

Not reported

6 months

Randomized trial in people · n = 60

Chen 1993

30 and 60 micrograms/kg/day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 43

Neyzi 1993

30 micrograms/kg/day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 43

Neyzi 1993

30 and 60 micrograms/kg/day

Human

human

Not reported

6 months

Randomized trial in people · n = 40

Chen 1993

10 micrograms/kg

Human

human

subcutaneous

16 weeks

Randomized trial in people · n = 19

Khorram 1997

10 microg/kg

Human

human

subcutaneous

16 weeks

Randomized trial in people · n = 19

Khorram 1997

60 ng/kg/minutes

Human

human

subcutaneous

24 h

Randomized trial in people · n = 12

Achermann 1999

10 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 10

Spoudeas 1994

100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 10

Spoudeas 1994

1 microgram

Human

human

intravenous

Not reported

Randomized trial in people · n = 10

Spoudeas 1994

10 and 100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 10

Spoudeas 1994

1, 10 and 100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 10

Spoudeas 1994

100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 9

Giustina 1993

0.05, 0.15 and 1.0 μg/kg

Human

human

intravenous bolus

single bolus

Randomized trial in people · n = 5

Achermann 2000

60 micrograms/kg/day

Human

human

subcutaneous

6 months

Randomized trial in people

Neyzi 1993

0.25 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people

Wilton 1993

1-2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people

Wilton 1993

about 50 micrograms/kg

Human

human

intranasal

Not reported

Randomized trial in people

Wilton 1993

30 micrograms/kg/day

Human

human

subcutaneous

up to 1 yr

Trial in people without random groups · n = 110

Thorner 1996

1 microgram/kg BW

Human

human

intravenous

single dose

Trial in people without random groups · n = 86

Ranke 1986

1 microgram/kg

Human

human

intravenous

single injection

Trial in people without random groups · n = 36

Gelander 1989

1 microgram/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 22

Ramirez 1995

20 micrograms/kg twice daily

Human

human

subcutaneous

12 months

Trial in people without random groups · n = 18

Kirk 1994

200 micrograms

Human

human

intravenous bolus

single dose

Trial in people without random groups · n = 17

Grossman 1985

5 micrograms/kg

Human

human

subcutaneous

6 months

Trial in people without random groups · n = 11

Hernández 1988

1 microg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 11

Bellone 2000

25 ng/kg.min

Human

human

intravenous

90 min

Trial in people without random groups · n = 10

Soule 1994

3-4 micrograms/kg b.d. or once daily, then 8-10 micrograms/kg once daily

Human

human

subcutaneous

11 months including treatment-free intervals

Trial in people without random groups · n = 9

Hümmelink 1987

3-4 micrograms/kg once daily

Human

human

subcutaneous

3 months

Trial in people without random groups · n = 9

Hümmelink 1987

3-4 micrograms/kg twice daily

Human

human

subcutaneous

3 months

Trial in people without random groups · n = 9

Hümmelink 1987

8-10 micrograms/kg once daily

Human

human

subcutaneous

3 months

Trial in people without random groups · n = 9

Hümmelink 1987

15 micrograms/kg twice daily

Human

human

subcutaneous

1 year

Trial in people without random groups · n = 9

Ogilvy-Stuart 1997

26 +/- 2.4 micrograms/kg/day

Human

human

subcutaneous

3 to 6 months

Trial in people without random groups · n = 9

Pasqualini 1996

60 ng/kg/min

Human

human

subcutaneous infusion

up to 1 year

Trial in people without random groups · n = 8

Brain 1990

50 micrograms/kg three times per day

Human

human

intranasal

6 months

Trial in people without random groups · n = 8

Hümmelink 1993

100 micrograms

Human

human

intravenous

single bolus

Trial in people without random groups · n = 7

Giustina 1989

0.015 to 0.5 micrograms/kg body weight

Human

human

intravenous bolus

Not reported

Trial in people without random groups · n = 5

Barron 1985

100 micrograms/kg body weight

Human

human

intranasal

Not reported

Trial in people without random groups · n = 5

Borkenstein 1986

0.1 and 1.0 micrograms/kg

Human

human

intravenous

two pulses weekly over 4 weeks

Trial in people without random groups · n = 4

Dattani 1996

Context

Route

Amount

How often

How long

Agreement

Sources

Nightly dosing for adult wellness or anti-aging

subcutaneous injectionabout 30 to 60 minutes before sleep, on an empty stomach

200 to 300 mcg per dose

once daily at bedtime; S2 says 5 to 7 nights a week

3 to 6 months, then a lower-frequency schedule

2 sources agree on 200-300 mcg at bedtime. Both are wikis that compile other pages. Both sources carry seller links.

S1S2

Higher doses prescribed by anti-aging clinics

subcutaneous injection

300 to 1000 mcg per dose

once daily at bedtime

6 to 12 months (S1)

sources differ: 500-1000 mcg (S1) against 300-500 mcg (S2). The range here is not an average. Both sources carry seller links.

S1S2

Stack with ipamorelin

subcutaneous injectionthe two are given together

200 to 300 mcg per dose of each peptide

once daily at bedtime

3 to 6 months

2 sources agree on 200-300 mcg of each peptide at bedtime. Both are wikis that compile other pages. Both sources carry seller links.

S1S2

Maintenance after the first months

subcutaneous injection

500 to 1000 mcg per dose

2 to 3 times per week

ongoing

single source. The source carries seller links.

Sermorelin

Sermorelin at a glance

What is sermorelin?

The history of sermorelin

Sermorelin structure and chemistry

What sermorelin studies show

Growth hormone and growth

Immune system and inflammation

Blood sugar

Hormones

Weight and appetite

Bones and joints

Key sermorelin studies

Sermorelin clinical trials

Is sermorelin approved?

Sermorelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about sermorelin

Related peptides

Tesamorelin vs sermorelin

Sources

Sermorelin

Sermorelin at a glance

What is sermorelin?

The history of sermorelin

Sermorelin structure and chemistry

What sermorelin studies show

Growth hormone and growth

Immune system and inflammation

Blood sugar

Hormones

Weight and appetite

Bones and joints

Key sermorelin studies

Sermorelin clinical trials

Is sermorelin approved?

Sermorelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about sermorelin

Related peptides

Tesamorelin vs sermorelin

Sources